Hancock Jaffe Laboratories Inc Net debt/EBITDA
Что обозначает Net debt/EBITDA в Hancock Jaffe Laboratories Inc?
Net debt/EBITDA Hancock Jaffe Laboratories Inc является 1.20
Какое определение для Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA компаний в Health Care сектор на NASDAQ по сравнению с Hancock Jaffe Laboratories Inc
Что делает Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Компании с net debt/ebitda похож на Hancock Jaffe Laboratories Inc
- Gold Springs Resource имеет Net debt/EBITDA из 1.19
- ObsEva SA имеет Net debt/EBITDA из 1.19
- Kenmare Resources plc имеет Net debt/EBITDA из 1.19
- EEStor имеет Net debt/EBITDA из 1.20
- China Leasing имеет Net debt/EBITDA из 1.20
- Midland имеет Net debt/EBITDA из 1.20
- Hancock Jaffe Laboratories Inc имеет Net debt/EBITDA из 1.20
- Outset Medical имеет Net debt/EBITDA из 1.20
- Invesco имеет Net debt/EBITDA из 1.20
- Kits Eyecare имеет Net debt/EBITDA из 1.20
- Dare Bioscience Inc имеет Net debt/EBITDA из 1.20
- Sierra Madre Gold and Silver имеет Net debt/EBITDA из 1.21
- Greenfirst Forest Products Inc имеет Net debt/EBITDA из 1.21